← Evidence map

ArticleBreast cancer research : BCR2012

CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Ling-Ming Tseng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

77 papers cite itlatest 60 shown

2012
…
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 22537901